| Everolimus for advanced pancreatic neuroendocrine tumors JC Yao, MH Shah, T Ito, CL Bohas, EM Wolin, E Van Cutsem, TJ Hobday, ... New England Journal of Medicine 364 (6), 514-523, 2011 | 3326 | 2011 |
| Phase 3 Trial of 177Lu-Dotatate for Midgut Neuroendocrine Tumors J Strosberg, G El-Haddad, E Wolin, A Hendifar, J Yao, B Chasen, E Mittra, ... New England Journal of Medicine 376 (2), 125-135, 2017 | 2763 | 2017 |
| Measurement of clinical and subclinical tumour response using [18F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations H Young, R Baum, U Cremerius, K Herholz, O Hoekstra, AA Lammertsma, ... European journal of cancer 35 (13), 1773-1782, 1999 | 1952 | 1999 |
| Lanreotide in metastatic enteropancreatic neuroendocrine tumors ME Caplin, M Pavel, JB Ćwikła, AT Phan, M Raderer, E Sedláčková, ... New England Journal of Medicine 371 (3), 224-233, 2014 | 1947 | 2014 |
| FDG PET and PET/CT: EANM procedure guidelines for tumour PET imaging: version 1.0 R Boellaard, MJ O’Doherty, WA Weber, FM Mottaghy, MN Lonsdale, ... European journal of nuclear medicine and molecular imaging 37, 181-200, 2010 | 1580 | 2010 |
| Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo … ME Pavel, JD Hainsworth, E Baudin, M Peeters, D Hörsch, RE Winkler, ... The Lancet 378 (9808), 2005-2012, 2011 | 1174 | 2011 |
| Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study JC Yao, N Fazio, S Singh, R Buzzoni, C Carnaghi, E Wolin, J Tomasek, ... The Lancet 387 (10022), 968-977, 2016 | 1136 | 2016 |
| German multicenter study investigating 177Lu-PSMA-617 radioligand therapy in advanced prostate cancer patients K Rahbar, H Ahmadzadehfar, C Kratochwil, U Haberkorn, M Schäfers, ... Journal of Nuclear Medicine 58 (1), 85-90, 2017 | 857 | 2017 |
| The joint IAEA, EANM, and SNMMI practical guidance on peptide receptor radionuclide therapy (PRRNT) in neuroendocrine tumours JJ Zaknun, L Bodei, J Mueller-Brand, ME Pavel, RP Baum, D Hörsch, ... European journal of nuclear medicine and molecular imaging 40, 800-816, 2013 | 846 | 2013 |
| Daily oral everolimus activity in patients with metastatic pancreatic neuroendocrine tumors after failure of cytotoxic chemotherapy: a phase II trial JC Yao, C Lombard-Bohas, E Baudin, LK Kvols, P Rougier, ... Journal of clinical oncology 28 (1), 69-76, 2010 | 794 | 2010 |
| NANETS treatment guidelines: well-differentiated neuroendocrine tumors of the stomach and pancreas MH Kulke, LB Anthony, DL Bushnell, WW De Herder, SJ Goldsmith, ... Pancreas 39 (6), 735-752, 2010 | 691 | 2010 |
| Prospective comparison of 18F-FDG PET with conventional imaging modalities (CT, MRI, US) in lymph node staging of head and neck cancer S Adams, RP Baum, T Stuckensen, K Bitter, G Hör European journal of nuclear medicine 25, 1255-1260, 1998 | 652 | 1998 |
| Consensus guidelines for the management and treatment of neuroendocrine tumors PL Kunz, D Reidy-Lagunes, LB Anthony, EM Bertino, K Brendtro, JA Chan, ... Pancreas 42 (4), 557-577, 2013 | 623 | 2013 |
| Processing of generator-produced 68Ga for medical application KP Zhernosekov, DV Filosofov, RP Baum, P Aschoff, H Bihl, AA Razbash, ... Journal of Nuclear Medicine 48 (10), 1741-1748, 2007 | 623 | 2007 |
| The NANETS consensus guideline for the diagnosis and management of neuroendocrine tumors: well-differentiated neuroendocrine tumors of the jejunum, ileum, appendix, and cecum JP Boudreaux, DS Klimstra, MM Hassan, EA Woltering, RT Jensen, ... Pancreas 39 (6), 753-766, 2010 | 595 | 2010 |
| Imaging of neuroendocrine tumors V Rufini, ML Calcagni, RP Baum Seminars in nuclear medicine 36 (3), 228-247, 2006 | 571 | 2006 |
| 68Ga-and 177Lu-labeled PSMA I&T: optimization of a PSMA-targeted theranostic concept and first proof-of-concept human studies M Weineisen, M Schottelius, J Simecek, RP Baum, A Yildiz, S Beykan, ... Journal of Nuclear Medicine 56 (8), 1169-1176, 2015 | 560 | 2015 |
| Limited value of fluorine-18 fluorodeoxyglucose positron emission tomography for the imaging of neuroendocrine tumours S Adams, R Baum, T Rink, PM Schumm-Dräger, KH Usadel, G Hör European journal of nuclear medicine 25, 79-83, 1998 | 511 | 1998 |
| Procedure guidelines for PET/CT tumour imaging with 68Ga-DOTA-conjugated peptides: 68Ga-DOTA-TOC, 68Ga-DOTA-NOC, 68Ga-DOTA-TATE I Virgolini, V Ambrosini, JB Bomanji, RP Baum, S Fanti, M Gabriel, ... European journal of nuclear medicine and molecular imaging 37, 2004-2010, 2010 | 495 | 2010 |
| 177Lu-labeled prostate-specific membrane antigen radioligand therapy of metastatic castration-resistant prostate cancer: safety and efficacy RP Baum, HR Kulkarni, C Schuchardt, A Singh, M Wirtz, S Wiessalla, ... Journal of Nuclear Medicine 57 (7), 1006-1013, 2016 | 482 | 2016 |
